CCRM supports the commercialization of regenerative medicine-based technologies, and cell and gene therapies, with strategic funding, dedicated infrastructure and specialized business and scientific expertise.
By partnering with leading research institutions to launch new ventures, enabling industry by providing innovative contract development and manufacturing organization (CDMO) services, and scaling emerging companies by catalyzing investment, CCRM is accelerating the translation of promising technologies, processes and therapies into life-changing health outcomes for patients.
A network of researchers, leading companies, strategic investors and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients, with specialized teams, funding, and infrastructure. CCRM is the commercialization partner of Medicine by Design and is hosted by the University of Toronto. In 2021, we celebrated our 10-year anniversary. Catch up on our story so far by reading “The CCRM story: 10 years in the making
,” on the Innovations of the World website.
How CCRM is building a sustainable cell and gene therapy ecosystem
Presented by Michael May, PhD, President and CEO of CCRM, this video provides an overview of how CCRM is building a sustainable cell and gene therapy ecosystem by catalyzing manufacturing capability, access to capital and talent development.